Cargando…

6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors

In this work, we describe the design, synthesis, and structure-activity relationship of 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as inhibitors of Casein kinase 2 (CK2). At first, we optimized the reaction conditions for the azide-nitrile cycloaddition in the series of 6-cyano-7-aminoazolopyr...

Descripción completa

Detalles Bibliográficos
Autores principales: Urakov, Grigoriy V., Savateev, Konstantin V., Kotovskaya, Svetlana K., Rusinov, Vladimir L., Spasov, Alexandr A., Babkov, Denis A., Sokolova, Elena V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783892/
https://www.ncbi.nlm.nih.gov/pubmed/36557833
http://dx.doi.org/10.3390/molecules27248697
_version_ 1784857681732829184
author Urakov, Grigoriy V.
Savateev, Konstantin V.
Kotovskaya, Svetlana K.
Rusinov, Vladimir L.
Spasov, Alexandr A.
Babkov, Denis A.
Sokolova, Elena V.
author_facet Urakov, Grigoriy V.
Savateev, Konstantin V.
Kotovskaya, Svetlana K.
Rusinov, Vladimir L.
Spasov, Alexandr A.
Babkov, Denis A.
Sokolova, Elena V.
author_sort Urakov, Grigoriy V.
collection PubMed
description In this work, we describe the design, synthesis, and structure-activity relationship of 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as inhibitors of Casein kinase 2 (CK2). At first, we optimized the reaction conditions for the azide-nitrile cycloaddition in the series of 6-cyano-7-aminoazolopyridimines and sodium azide. The regioselectivity of this process has been shown, as the cyano group of the pyrimidine cycle was converted to tetrazole while the nitrile of the azole fragment did not react. The desired tetrazolyl-azolopyrimidines were obtained in a moderate to excellent yields (42–95%) and converted further to water soluble sodium salts by the action of sodium bicarbonate. The obtained 6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidines 2a–k and their sodium salts 3a–c, 3g–k showed nano to low micromolar range of CK2 inhibition while corresponding [1,2,4]triazolopyrimidines 10a–k were less active (IC(50) > 10 µM). The leader compound 3-phenyl-6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidine 2i as CK2 inhibitor showed IC(50) 45 nM.
format Online
Article
Text
id pubmed-9783892
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97838922022-12-24 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors Urakov, Grigoriy V. Savateev, Konstantin V. Kotovskaya, Svetlana K. Rusinov, Vladimir L. Spasov, Alexandr A. Babkov, Denis A. Sokolova, Elena V. Molecules Article In this work, we describe the design, synthesis, and structure-activity relationship of 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as inhibitors of Casein kinase 2 (CK2). At first, we optimized the reaction conditions for the azide-nitrile cycloaddition in the series of 6-cyano-7-aminoazolopyridimines and sodium azide. The regioselectivity of this process has been shown, as the cyano group of the pyrimidine cycle was converted to tetrazole while the nitrile of the azole fragment did not react. The desired tetrazolyl-azolopyrimidines were obtained in a moderate to excellent yields (42–95%) and converted further to water soluble sodium salts by the action of sodium bicarbonate. The obtained 6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidines 2a–k and their sodium salts 3a–c, 3g–k showed nano to low micromolar range of CK2 inhibition while corresponding [1,2,4]triazolopyrimidines 10a–k were less active (IC(50) > 10 µM). The leader compound 3-phenyl-6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidine 2i as CK2 inhibitor showed IC(50) 45 nM. MDPI 2022-12-08 /pmc/articles/PMC9783892/ /pubmed/36557833 http://dx.doi.org/10.3390/molecules27248697 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Urakov, Grigoriy V.
Savateev, Konstantin V.
Kotovskaya, Svetlana K.
Rusinov, Vladimir L.
Spasov, Alexandr A.
Babkov, Denis A.
Sokolova, Elena V.
6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors
title 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors
title_full 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors
title_fullStr 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors
title_full_unstemmed 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors
title_short 6-(Tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as Novel Potent CK2 Inhibitors
title_sort 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as novel potent ck2 inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783892/
https://www.ncbi.nlm.nih.gov/pubmed/36557833
http://dx.doi.org/10.3390/molecules27248697
work_keys_str_mv AT urakovgrigoriyv 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors
AT savateevkonstantinv 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors
AT kotovskayasvetlanak 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors
AT rusinovvladimirl 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors
AT spasovalexandra 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors
AT babkovdenisa 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors
AT sokolovaelenav 6tetrazol5yl7aminoazolo15apyrimidinesasnovelpotentck2inhibitors